Fig. 1From: In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer’s disease phasesFlow diagram showing the number of subjects/patients who underwent [123I]FP-CIT SPECT imaging and were initially screened for the present study. Red arrows indicate those individuals that were excludedBack to article page